Basis of PD1/PD-L1 Therapies

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Tumor cells utilize immune checkpoints, including programmed death-1 receptor (PD-1) and its ligands (PD-L1, PD-L2), to evade immune surveillance.
• The PD-1/PD-L1 interaction promotes self-tolerance, making these molecules key targets for T cell-based immunotherapies.

Purpose of the Study:

• To summarize current knowledge on PD-1 and PD-L1 genes, their expression, regulation, and clinical significance.
• To address the need for better insight into PD-1/PD-L1 expression for predicting therapy response.

Main Methods:

• Review of existing literature on PD-1 and PD-L1 genes and their roles in cancer immunology.
• Analysis of molecular mechanisms regulating PD-1/PD-L1 expression.
• Evaluation of the association between PD-1/PD-L1 and clinical parameters.

Main Results:

• PD-1 and PD-L1 are critical in immune evasion and immunotherapy targets.
• Therapeutic efficacy of checkpoint inhibitors is variable, with limited long-term responses and development of resistance.
• The predictive and prognostic value of PD-1/PD-L1 is debated due to methodological and dynamic expression variability.

Conclusions:

• Further research into PD-1/PD-L1 expression, regulation, and clinical relevance is essential.
• A deeper understanding can optimize T cell-based immunotherapies and improve patient stratification and treatment outcomes.